Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study aimed to identify whether frailty is associated with the time between surgery and the initiation of chemotherapy for patients with ovarian cancer.
Methods: This retrospective cohort study included patients 18 years or older with stage II to IV ovarian cancer who underwent primary debulking surgery at a tertiary medical center between July 2006 and July 2015. Basic demographics and clinical information were obtained from a departmental database and the electronic medical record. The Modified Frailty Index (mFI) was calculated based on 10 comorbidities and functional status yielding 11 items total. Patients were categorized by a total score: 0-1=no frailty, 2=moderate frailty and 3+=high frailty.
Results: Among 451 patients, 359 had mFI scores of 0-1, 60 had a score of 2, and 32 had scores of 3+. Mean time from surgery to initiation of chemotherapy was 37 days. Mean number of days between surgery and initiation of chemotherapy increased with increasing frailty score: 36 days for the not frail group, 39 days for the moderate frailty group, and 54 days for the high frailty group (p<0.001). Time to initiation of chemotherapy of 42 days or more occurred in 23% of the no frailty group, 28% in the moderate frailty group, and 63% in the high frailty group (p<0.001). Overall survival decreased with increasing frailty scores.
Conclusion: High mFI scores lead to a greater delay between surgery and chemotherapy initiation. Being able to predict delays in initiation of chemotherapy may allow oncologists to consider neoadjuvant chemotherapy, pre-habilitation before surgery, and improved preoperative counseling in high-risk patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ijgc-2022-003603 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.
Obesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
Efficacy of Step-down Infusion Method of a Novel Barbiturate Therapy for Severe Subarachnoid Hemorrhage with Intracerebral Hematoma.
Neurol Med Chir (Tokyo)
September 2025
Department of Neurosurgery, Kurume University School of Medicine.
Currently, there is no effective treatment for elevated intracranial pressure in the acute phase of subarachnoid hemorrhage. Recently, we developed "step-down infusion of barbiturate," a therapeutic strategy for severe traumatic brain injury, which decreased intracranial pressure and significantly reduced mortality without serious side effects. This study aimed to examine the efficacy of step-down infusion of barbiturate in patients with severe subarachnoid hemorrhage.
View Article and Find Full Text PDFRisk Factors for Incidental Durotomy in Initial Posterior Decompression Surgery for Lumbar Central Canal Stenosis with Bilateral Neurogenic Claudication.
World Neurosurg
September 2025
Department of Orthopaedic Surgery, The University of Tokyo 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan; University of Tokyo Spine Group (UTSG), 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. Electronic address:
Objective: To identify significant risk factors for incidental durotomy (ID) in initial posterior decompression surgery for lumbar central canal stenosis and to explore whether these risks vary by surgical approach through subgroup analyses.
Methods: This study included patients who underwent single-level posterior decompression surgery for lumbar central canal stenosis with bilateral neurogenic claudication at eight hospitals between April 2017 and May 2023. Patient demographics, comorbidities, and surgical details, including surgeon certification status, were collected.
Safety and Feasibility of Lumbar CSF Drainage with Intrathecal Pressure Monitoring in Acute Severe Spinal Cord Injury: A Randomized Pilot Trial.
World Neurosurg
September 2025
Department of Spinal Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Electronic address:
Background: Spinal cord perfusion impairment is a critical secondary mechanism in acute spinal cord injury (SCI). Although lumbar cerebrospinal fluid (CSF) drainage is widely used in cardiothoracic surgery, its use in SCI remains limited. This study presents an evaluation of the safety and feasibility of lumbar CSF drainage with intrathecal pressure (ITP) and spinal cord perfusion pressure (SCPP) monitoring in acute SCI patients.
View Article and Find Full Text PDFImpact of Subdural Drain Omission on Recurrence After Chronic Subdural Hematoma Surgery: A Retrospective Study.
World Neurosurg
September 2025
Department of Neurosurgery, St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address:
Although subdural drain (SDD) placement reduces recurrence after burr-hole surgery for chronic subdural hematoma (CSDH), complications have led our institution to discontinue its routine use. During the first year following this change, the recurrence rate was 14.6%, comparable to the recurrence rate observed prior to discontinuation.
View Article and Find Full Text PDF